Nonfilter and filter cigarette consumption and the incidence of lung cancer by histological type in Japan and the United States: Analysis of 30-year data from population-based cancer registries

2010 ◽  
Vol 128 (8) ◽  
pp. 1918-1928 ◽  
Author(s):  
Hidemi Ito ◽  
Keitaro Matsuo ◽  
Hideo Tanaka ◽  
Devin C. Koestler ◽  
Hernando Ombao ◽  
...  
Keyword(s):  
United States ◽  
Lung Cancer ◽  
Cancer Registries ◽  
The United States ◽  
Population Based ◽  
Histological Type ◽  
Cigarette Consumption

scholarly journals Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries

2021 ◽  
pp. 641-653
Author(s):  
Anne-Michelle Noone ◽  
Clara J. K. Lam ◽  
Angela B. Smith ◽  
Matthew E. Nielsen ◽  
Eric Boyd ◽  
...  
Keyword(s):  
United States ◽  
Machine Learning ◽  
Bladder Cancer ◽  
Cancer Incidence ◽  
Cancer Registries ◽  
The United States ◽  
Population Based ◽  
Learning Methods ◽  
Machine Learning Methods ◽  
Classification And Regression

PURPOSE Population-based cancer incidence rates of bladder cancer may be underestimated. Accurate estimates are needed for understanding the burden of bladder cancer in the United States. We developed and evaluated the feasibility of a machine learning–based classifier to identify bladder cancer cases missed by cancer registries, and estimated the rate of bladder cancer cases potentially missed. METHODS Data were from population-based cohort of 37,940 bladder cancer cases 65 years of age and older in the SEER cancer registries linked with Medicare claims (2007-2013). Cases with other urologic cancers, abdominal cancers, and unrelated cancers were included as control groups. A cohort of cancer-free controls was also selected using the Medicare 5% random sample. We used five supervised machine learning methods: classification and regression trees, random forest, logic regression, support vector machines, and logistic regression, for predicting bladder cancer. RESULTS Registry linkages yielded 37,940 bladder cancer cases and 766,303 cancer-free controls. Using health insurance claims, classification and regression trees distinguished bladder cancer cases from noncancer controls with very high accuracy (95%). Bacille Calmette-Guerin, cystectomy, and mitomycin were the most important predictors for identifying bladder cancer. From 2007 to 2013, we estimated that up to 3,300 bladder cancer cases in the United States may have been missed by the SEER registries. This would result in an average of 3.5% increase in the reported incidence rate. CONCLUSION SEER cancer registries may potentially miss bladder cancer cases during routine reporting. These missed cases can be identified leveraging Medicare claims and data analytics, leading to more accurate estimates of bladder cancer incidence.

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

Blood ◽  
2008 ◽  
Vol 112 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Dana E. Rollison ◽  
Nadia Howlader ◽  
Martyn T. Smith ◽  
Sara S. Strom ◽  
William D. Merritt ◽  
...  
Keyword(s):  
United States ◽  
Myelodysplastic Syndromes ◽  
Survival Rates ◽  
Myeloproliferative Disorders ◽  
Cancer Registries ◽  
The United States ◽  
Population Based ◽  
Incidence Rates ◽  
Chronic Myeloproliferative Disorders ◽  
The North

Abstract Reporting of myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based cancer registries in the United States was initiated in 2001. In this first analysis of data from the North American Association of Central Cancer Registries (NAACCR), encompassing 82% of the US population, we evaluated trends in MDS and CMD incidence, estimated case numbers for the entire United States, and assessed trends in diagnostic recognition and reporting. Based on more than 40 000 observations, average annual age-adjusted incidence rates of MDS and CMD for 2001 through 2003 were 3.3 and 2.1 per 100 000, respectively. Incidence rates increased with age for both MDS and CMD (P < .05) and were highest among whites and non-Hispanics. Based on follow-up data through 2004 from the Surveillance, Epidemiology, and End Results (SEER) Program, overall relative 3-year survival rates for MDS and CMD were 45% and 80%, respectively, with males experiencing poorer survival than females. Applying the observed age-specific incidence rates to US Census population estimates, approximately 9700 patients with MDS and 6300 patients with CMD were estimated for the entire United States in 2004. MDS incidence rates significantly increased with calendar year in 2001 through 2004, and only 4% of patients were reported to registries by physicians' offices. Thus, MDS disease burden in the United States may be underestimated.

Ovarian cancer treatment patterns and outcomes in the United States: A National Program of Cancer Registries (NPCR) study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15031-15031 ◽  
Author(s):  
S. L. Stewart ◽  
J. M. Wike ◽  
R. Cress ◽  
C. O’Malley ◽  
S. Neloms ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
New York ◽  
Standard Of Care ◽  
Cancer Registries ◽  
The United States ◽  
Population Based ◽  
Simple Random Sample ◽  
Northern California ◽  
Patients Âgés

15031 Background: Ovarian cancer (ovca) is the fifth leading cause of cancer death among women in the United States. In 2001, the NPCR program (administered by the Centers for Disease Control and Prevention) initiated a multi-year study to determine the first course of treatment for ovca patients in order to assess whether the ovca standard of care (as defined by the NIH Physician Data Query) was met. Methods: Population-based cancer registries in Maryland, New York, and Northern California were funded to collect patient, tumor, provider, and treatment data on patients diagnosed in these areas between 1997 and 2000. Information was collected through a retrospective medical record abstraction; all ovca records in Northern California and Maryland were included in the study, a simple random sample of ovca medical records in New York was included. Data on over 3000 patients from Northern California and New York were obtained (about 1500 patients each); data on about 1000 patients from Maryland was obtained. Patient vital status was followed through 2002. Results: Most patients were non-Hispanic white and between the ages of 50 and 79. About 30% of the tumors were papillary serous cystadenocarcinomas and almost 40% were poorly differentiated; about 66% of tumors were distant stage at diagnosis. The percentage of distant stage diagnoses increased with increasing age through age 79. Over half of patients were treated by gynecologic oncologists; obstetrician/gynecologists treated a little over 10% of patients. Overall, over 80% of patients underwent cancer directed surgery; about 50% were treated with carboplatin and about 55% were treated with paclitaxel. Patients ages 70 and older received cancer-directed surgery less often than younger patients. Overall, about 50% of patients were alive at the end of the follow-up period, with the percentage alive within age categories decreasing with increasing age. Conclusions: Age remains a negative factor in ovca presentation, treatment, and survival. Continued assessment of ovca patterns of care will enhance ovca knowledge and may aid clinicians in determining appropriate treatments for their ovca patients. No significant financial relationships to disclose.

scholarly journals BSCI-06. FREQUENCY OF BRAIN METASTASIS FROM BREAST AND LUNG CANCER IN THE UNITED STATES -- A POPULATION-BASED ASSESSMENT

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i2-i2
Author(s):  
Quinn Ostrom ◽  
Mustafa Ascha ◽  
Carol Kruchko ◽  
Jill Barnholtz-Sloan
Keyword(s):  
United States ◽  
Lung Cancer ◽  
Linked Data ◽  
Triple Negative ◽  
Population Level ◽  
The United States ◽  
Population Based ◽  
Small Cell ◽  
Cancer Site ◽  
Central Nervous System Tumor

Abstract BACKGROUND: Brain metastases (BM) are the most common central nervous system tumor in the United States and occur with increasingly frequency due to improved screening and therapeutics leading to improved survival. Current estimates of frequency of BM vary significantly by cancer site and are typically not population-based. Population-based estimates of incidence have recently become possible due to collection of data on BM identified at diagnosis (“synchronous” BM, SBM). BM may occur at any point after cancer diagnosis. We report our recent population-based estimates of SBM and period incidence of BM (PBM) from breast (BC) and lung cancer (LC). METHODS: Data from Surveillance, Epidemiology, and End Results (SEER, 2010–2016 diagnoses) were used to estimate SBM and linked data from SEER-Medicare (2008–2012 diagnoses for individuals 65+, with 2007–2014 claims) were used to estimate PBM, for BC and LC overall and by BC and LC subtypes. RESULTS: Within the SEER data, 10.9% of LC cases presented with SBM (15.5% in small cell LC [SCLC], and 10.8% in non-small cell LC [NSCLC]); 0.4% of BC cases presented with SBM, 0.7% in triple negative (TNBC), 0.8% for HER2+, and 0.2% for ER+\PR+\HER2-. Within the SEER-Medicare data, 13.5% of LC overall had LBM with 23.1% for SCLC and 15.3% for NSCLC; 1.8% of BC overall had LBM with 4.2% in triple negative (TNBC), 3.1% for HER2+, and 1.1% for ER+\PR+\HER2. CONCLUSION: Frequency of synchronous and period BM varies by originating site as well as subtype. The new SBM variable in SEER allows for estimation of this important statistic, while the SEER-Medicare linked data allows for estimation of PBM, both on a population-level for the US population. These estimates are useful to clinical practice and critical for estimating morbidity and mortality due to BM.

scholarly journals Incidence of Benign Meningiomas in the United States: Current and Future Trends

2021 ◽  
Author(s):  
Sonia Bhala ◽  
Douglas R Stewart ◽  
Victoria Kennerley ◽  
Valentina I Petkov ◽  
Philip S Rosenberg ◽  
...  
Keyword(s):  
United States ◽  
Age Groups ◽  
Cancer Registries ◽  
Health Impact ◽  
The United States ◽  
Birth Cohorts ◽  
Benign Meningioma ◽  
Case Count ◽  
Future Burden ◽  
Rate Ratios

Abstract Background Benign meningiomas are the most frequently reported central nervous system tumors in the United States (US), with increasing incidence in past decades. However, the future trajectory of this neoplasm remains unclear. Methods We analyzed benign meningioma incidence of cases identified by any means (eg, radiographically with or without microscopic confirmation) in US Surveillance Epidemiology and End Results (SEER) cancer registries among 35–84-year-olds during 2004–2017 by sex and race/ethnicity using age-period-cohort (APC) models. We employed APC forecasting models to glean insights regarding the etiology, distribution, and anticipated future (2018–2027) public health impact of this neoplasm. Results In all groups, meningioma incidence overall increased through 2010, then stabilized. Temporal declines were statistically significant overall and in most groups. JoinPoint analysis of cohort rate-ratios identified substantial acceleration in White men born after 1963 (from 1.1% to 3.2% per birth year); cohort rate-ratios were stable or increasing in all groups and all birth cohorts. We forecast that meningioma incidence through 2027 will remain stable or decrease among 55–84-year-olds but remain similar to current levels among 35–54-year-olds. Total meningioma burden in 2027 is expected to be approximately 30,470 cases, similar to the expected case count of 27,830 in 2018. Conclusions Between 2004–2017, overall incidence of benign meningioma increased and then stabilized or declined. For 2018–2027, our forecast is incidence will remain generally stable in younger age groups but decrease in older age groups. Nonetheless, the total future burden will remain similar to current levels because the population is aging.

Sign in / Sign up

Export Citation Format

Share Document